Neoplasms

Symptoms and General Pathology

All Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Rare Diseases

Neoplasm Metastasis

Colorectal Neoplasms

Carcinoma

Adenocarcinoma

Neuroendocrine Tumors

Liver Neoplasms

Intestinal Neoplasms

Pancreatic Neoplasms

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Neoplastic Processes

Liver Diseases

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Stomach Diseases

Neuroendocrine Tumor

Gastro-enteropancreatic Neuroendocrine Tumor

Pancreatic Cancer

Stomach Cancer

Neuroepithelioma

Hematinics

All Drugs and Chemicals

Liver Extracts

* 60Gy in 3 fractions (20Gy/fraction) over 14 days
* 60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above

SBRT

Andre TC Chen, MD, PhD

Karina Moutinho, MD

Andre TC Chen, MD

Rachel Riechelman, MD, PhD

This is a Phase II study to determine the efficacy of SBRT to treat liver metastases in patients with Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors that are not amenable to surgery. Patients should have no evidence of extra-hepatic disease or have disease that is planned to be treated with curative intent.

Therefore, SBRT is being considered as a potentially curative procedure.

Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases

Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors

- Local Progression Free Survival of treated lesions in evaluable patients. Local Progression Free Survival will be defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria applied to the Planning Target Volume (PTV) and 1cm around (assessment of marginal failure).

Time-to-events will be counted from the date of initiation of treatment. Patients will be considered evaluable if followed for at least 6 months after SBRT. A review after 6 months is due to the transient changes after irradiation that make uncertain radiological evaluation before 6 months.

treatment related toxicity evaluated by the Common Toxicity Criteria for Adverse Effects (CTCAE) v. 4

Instituto do Cancer do Estado de São Paulo

University of Sao Paulo

MD, PhD

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Prostatic Neoplasms

Sarcoma

Soft Tissue Sarcoma

Gastrointestinal Agents

Pancrelipase

Pancreatin

MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.

Ergun Ahunbay, PhD

The purpose of this study is to determine if it would be helpful to use advanced MRI imaging techniques to take additional views of the tumor target for radiation treatment planning or treatment follow-up MRI.

The results of this research project will be used to establish a standard MRI protocol specific to each tumor or disease site. An MRI protocol is a list of MR image types that are acquired for each disease site. These images are used to generate the patient's treatment plan.

Advanced MRI Sequences for Radiation Therapy Treatment Planning

Investigation on the Utility of Advanced MRI Imaging Methods for Radiation Therapy Treatment Planning

We tested these Advanced MR protocols to evaluate which ones would best visualize the target region. This helped us determine the optimum MR SIM protocols for different sites that became clinical standard.

Medical College of Wisconsin

Chief of Physics

MRI for Treatment Planning or Follow up

Age, Categorical

Sex: Female, Male

Ergun Ahunbay

Patients aged 18 years and older of any race or gender with brain, head and neck, breast, lung, cervix, sarcoma, pancreatic, or prostate cancer undergoing MRI scans for radiation treatment planning and/or treatment follow-up at FMLH.

Number of Participants Successfully Contributing MRI Data

Overall Study

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases	NCT02185443	Liver Metastase... Colorectal Canc... Anal Canal Canc... Gastrointestina...	SBRT	18 Years -	University of Sao Paulo
Advanced MRI Sequences for Radiation Therapy Treatment Planning	NCT02340715	Cancer		18 Years - 89 Years	Medical College of Wisconsin
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases	NCT02185443	Liver Metastase... Colorectal Canc... Anal Canal Canc... Gastrointestina...	SBRT	18 Years -	University of Sao Paulo

Spots Global Cancer Trial Database for anal canal

Every month we try and update this database with for anal canal cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for anal canal

Every month we try and update this database with for anal canal cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for anal canal cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.